Immunotherapy added to chemotherapy improves pathological complete response in early triple negative breast cancer

Bookmark and Share
Published: 29 Sep 2019
Views: 607
Prof Peter Schmid - St Bartholomew's Hospital London, London, UK

Prof Peter Schmid presents data from the KEYNOTE-522 trial during a press conference at the 2019 ESMO congress.

This was a phase III trial looking at immunotherapy added to chemotherapy in early triple negative breast cancer.

Watch Prof Schmid's interview with ecancer here.

Read more about the study here.